The field of cancer immunotherapy has gained significant attention as a promising therapeutic approach, especially in light of the increasing failure rates of conventional treatments such as surgery, chemotherapy, and radiotherapy. Despite the potential of immunotherapy to enhance cytotoxic responses, its clinical success has been limited. This limitation is largely due to the scarcity of neoantigens and the challenges in delivering them effectively to elicit an immune response in cancer patients. The tumor immune microenvironment (TIME) further complicates this by acting as a barrier to immune infiltration and normal cellular function. Recent advancements in neoantigen-targeted immunotherapy have shown promise, particularly in the recognition of tumor-specific neoantigens with high immunogenicity. However, the mechanisms by which cancer cells influence the immune composition of TIME remain unclear, and the lack of effective predictive biomarkers and neoantigens continues to hinder precise immunotherapy responses. Understanding the interplay between TIME and neoantigens is crucial for developing more effective cancer immunotherapies, as it may help overcome immune evasion and resistance, leading to better treatment outcomes.This Research Topic aims to explore the complex interactions between the tumor immune microenvironment and neoantigens to enhance the efficacy of cancer immunotherapies. By investigating the mechanisms underlying neoantigen-induced anti-tumor immune responses and the modulation of TIME by cancer cells, the research seeks to address the challenges of immune evasion and resistance. The goal is to identify effective predictive biomarkers and develop strategies to streamline neoantigen-based immunotherapies, ultimately advancing personalized and effective cancer treatments.To gather further insights into the interplay between the tumor immune microenvironment and neoantigens, we welcome articles addressing, but not limited to, the following themes:- How neoantigen generation is influenced by the TIME, including the role of immune cells, cytokines, and other factors in neoantigen presentation.- The contribution of TIME to immunosuppression and immune escape, and the mechanisms by which neoantigens can overcome these barriers.- Regulation of immune cell infiltration and activation by the TIME, and factors that promote or inhibit the antitumor immune response.- Current and emerging approaches for targeting neoantigens in immunotherapy, including cancer vaccines, adoptive cell therapy, and antibody-based therapy.- Improved computational methods to predict potential neoantigens.
The field of cancer immunotherapy has gained significant attention as a promising therapeutic approach, especially in light of the increasing failure rates of conventional treatments such as surgery, chemotherapy, and radiotherapy. Despite the potential of immunotherapy to enhance cytotoxic responses, its clinical success has been limited. This limitation is largely due to the scarcity of neoantigens and the challenges in delivering them effectively to elicit an immune response in cancer patients. The tumor immune microenvironment (TIME) further complicates this by acting as a barrier to immune infiltration and normal cellular function. Recent advancements in neoantigen-targeted immunotherapy have shown promise, particularly in the recognition of tumor-specific neoantigens with high immunogenicity. However, the mechanisms by which cancer cells influence the immune composition of TIME remain unclear, and the lack of effective predictive biomarkers and neoantigens continues to hinder precise immunotherapy responses. Understanding the interplay between TIME and neoantigens is crucial for developing more effective cancer immunotherapies, as it may help overcome immune evasion and resistance, leading to better treatment outcomes.This Research Topic aims to explore the complex interactions between the tumor immune microenvironment and neoantigens to enhance the efficacy of cancer immunotherapies. By investigating the mechanisms underlying neoantigen-induced anti-tumor immune responses and the modulation of TIME by cancer cells, the research seeks to address the challenges of immune evasion and resistance. The goal is to identify effective predictive biomarkers and develop strategies to streamline neoantigen-based immunotherapies, ultimately advancing personalized and effective cancer treatments.To gather further insights into the interplay between the tumor immune microenvironment and neoantigens, we welcome articles addressing, but not limited to, the following themes:- How neoantigen generation is influenced by the TIME, including the role of immune cells, cytokines, and other factors in neoantigen presentation.- The contribution of TIME to immunosuppression and immune escape, and the mechanisms by which neoantigens can overcome these barriers.- Regulation of immune cell infiltration and activation by the TIME, and factors that promote or inhibit the antitumor immune response.- Current and emerging approaches for targeting neoantigens in immunotherapy, including cancer vaccines, adoptive cell therapy, and antibody-based therapy.- Improved computational methods to predict potential neoantigens.